[Haibu Pharmaceutica♣¥λ÷l] Pregabalin oral solution has πβsuccessfully been selected in t∞φhe tenth batch of national cent€γ∞ralized procurement!
Classification:
Company News
Recent Events
Release time:
2024-12-16
On December 13, 2024, a♣•¥t the recently concluded op©☆±$ening meeting of the t✔•enth batch of national drug centralize★→d procurement, the ora←↔l solution of pregabalin♥ developed by Haibu Pharma§☆★≥ceutical was successfully select↕>ed!
01. Ruianxi® Pregabalin Ora®↑₩l Solution
The pregabalin oral so£>ε♠lution has been approved forβ∑↕δ multiple indications worldwide₩∞, including postherpetic neuralgia,₹ fibromyalgia, neuropath' ic pain due to spinal c₩♦ord injury, diabetic peripheral neuropa♠thy, and as an adjunct★$ive therapy for partial seizures in pa≈♦tients aged one month and older. Bot₽☆h domestic and international ♣ ¥guidelines consistently reco✔™mmend pregabalin as the firstλ∑-line treatment for postherpe≈γtic neuralgia (PHN) and fibromyaπ$♣lgia (FM).
Our product is equipped with a pr"✘ecise drug delivery devi ↔€βce, making dose adjus ↑tments more convenient; at the'™ same time, the oral solution fo→≤£rm is easier to swallow than solid≠' formulations, making it the™¶±↕ first choice for elderly pati§"♥✔ents and those with swallowing di→÷Ωfficulties due to epilepsy, ©"stroke, or postherpetic neuralgia.$γ
02. Strength Creates☆€∏δ Quality - The Significance of Cent↕ ∑↑ralized Procurement is Major
Ruianxi® Pregabalin Oral Sol©ution has successfully been selected in♦" the tenth batch of national c× entralized procurement! This is not onlβ₩♥y a high recognition o≈♣ βf Haibu Pharmaceutical's com★∞pliance qualifications and product quaεlity but also a great ble¥↓•ssing for many patients. With th¥∞>✔e implementation of the cent§∞ralized procurement policy, Ruianxi♥π∏® Pregabalin Oral Solution wil•λ l be available at more favo™'↑"rable prices and broader coverage, ≥•benefiting more patients and efγ≥δfectively reducing th₩×'σeir medication burden.
At the same time, Haibu P§™♥harmaceutical will take this ←±∞successful selection in the n♣λ☆ational centralized procurement as an o•≠pportunity to continuously improve prod™↕±"uct quality and technological γβ₹innovation capabilities, launchin∞☆≈g more high-quality, ≥efficient, and safe pharmaceuti©cal products, allowing more patien≈÷÷ts to access affordable and high-qualit →y medicines, bringin≥₽¶g happiness and hope to the p↕σ'ublic!
Beijing Haibu Pharmaceutical T¥±echnology Co., Ltd. (referred to as "↑ ₩πHaibu Pharmaceuticalα ") was established in 200βγ÷5 and is a high-tech e★"∑☆nterprise with "chemical dr ÷ ug research and development" as &¶its core capability. ♦< It has a research and development cen&<φ¶ter in Beijing, a pilot verification ∞±center for raw materia↓₽$ls and formulations, and a G$φMP industrial production ba€δse, mainly engaged in the technical develop®δ↔ment and transfer of chemical× ™★ drugs, MAH researchε≠∑↕ and holding certifiφ♣cates, related applications for raw β↔₽materials, and commercial supply oγ≠ f pharmaceutical intermediates. and the application for innovative →™and improved drug research and deve↑→ lopment, it has been aw¥←'arded the title of "Top 20 Pharmace≈∏£utical R&D Compani∞₹es in China" for seve'&πral consecutive years and rec↓ ♣ognized as "Beijing Science and×✘≥ Technology Research and↑≥ € Development Institution," "Natio♠φ nal High-tech Enterpris±↑<e," and "Beijing Yizhβ£∑←uang Enterprise Innovation C≥✔™↑enter."
Haibu Pharmaceutical has rich experien←<"ce in the research and≈< production transfer, registrationγ"♥ , and application of various ε€∑λdosage forms such as chemical raw ★♥materials, oral solids, liquid p★&€reparations, sterile injΩ&ections, and external prepara§←tions. The R&D produc>∞♥ts cover multiple therapeutic are∞±≈"as including anti-tumor, anti-depress★§ion, anti-epilepsy, anti-anxiety,™©≤ cardiovascular, dig<✔≥estive system, and respiratory sy"≈←€stem.
Beijing Hope Pharmaceutic∏♥al Co., Ltd.
